Antengene Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors
prnewswire.com
news
2022-05-31 00:30:00

The STAMINA-001 study will evaluate the safety, pharmacology and preliminary efficacy of ATG-037 as a monotherapy or in combination with pembrolizumab, an immune checkpoint inhibitors (ICIs), in patients with locally advanced or metastatic solid tumors
ATG-037 is an orally-available, small molecule CD73 inhibitor. Antengene has exclusive globalÂ rights to develop, commercialize and manufacture ATG-037

SHANGHAI and HONG KONG, May 30, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.
